Guardian Pharmacy Services, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRDN research report →
Range $49 – $52
Price Chart
About the company
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States.
- CEO
- Fred Burke
- IPO
- 2024
- Employees
- 3,600
- HQ
- Atlanta, GA, US
Get TickerSpark's AI analysis on GRDN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.97B
- P/E
- 39.78
- Fwd P/E
- 34.41
- PEG
- 0.50
- P/S
- 2.04
- P/B
- 11.13
- EV/EBITDA
- 22.34
- Div Yield
- 0.00%
- Gross Margin
- 22.45%
- Op Margin
- 6.86%
- Net Margin
- 5.13%
- ROE
- 31.83%
- ROIC
- 22.57%
Latest fiscal year · YoY change
- Revenue
- $1.45B+17.9%
- Gross Profit
- $282.04M+15.4%
- Op Income
- $88.91M
- Net Income
- $49.22M+156.4%
- EPS
- $0.79+144.6%
- OCF Growth
- +73.0%
- FCF Growth
- +94.1%
- 52W High
- $50.85
- 52W Low
- $26.34
- 50D MA
- $42.97
- 200D MA
- $39.20
- Beta
- 0.10
- RSI (14)
- 56
- Avg Volume
- 545.36K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Guardian reported another strong quarter, with resident and prescription growth, higher gross profit and EBITDA, and an increased full-year 2026 outlook despite reported revenue pressure from IRA-related drug price reductions.· November 5, 2026
- Residents served rose to approximately 218,000, up high single digits year over year, and prescription volumes increased 10%.
- Reported revenue was $371 million versus $377 million a year ago; management said revenue would have risen high single digits excluding IRA-related price reductions.
- Gross profit increased 14% to $85.2 million, gross margin improved to 23%, and adjusted EBITDA rose 24% to $33.9 million.
- The company raised 2026 guidance to $1.44 billion-$1.46 billion of revenue and $136 million-$138 million of adjusted EBITDA.
- Management highlighted continued expansion through greenfield openings and acquisitions, plus a push toward better reimbursement economics and generic mix alignment.
Reported revenue was $371 million, down 1.7% from $377 million in the prior-year quarter. Gross profit was $85.2 million, up 14% year over year, and gross margin improved sequentially to 23%. Adjusted SG&A was $57.4 million, or 15.5% of revenue, and adjusted EBITDA increased 24% year over year to $33.9 million, with EBITDA margin at 9.1%. Net income was $19 million versus $9.6 million a year ago, and the effective tax rate was 26%. For full-year 2026, management raised guidance to revenue of $1.44 billion-$1.46 billion and adjusted EBITDA of $136 million-$138 million, assuming no additional acquisitions beyond those already completed.
Fred Burke said the company is seeing strong momentum across the business and believes its model is well insulated from broader economic pressures because of its cash generation, debt-free balance sheet, and exposure to private-pay assisted living. He emphasized that Guardian is pushing a reimbursement model that better reflects the value of its services and its generic-heavy dispensing mix, which he said should help de-risk the business over time. His tone was confident and constructive, with repeated comments that the company is positioned for durable growth and shareholder value.
Will Mudd said the quarter benefited from solid growth in residents served, prescription volumes, and adjusted EBITDA, alongside improved reimbursement, purchasing initiatives, plan optimization, and vaccine program execution. He cited approximately $120 million in cash and no debt at quarter-end, and said acquisitions and greenfield startups completed since 2024 were contributing positive adjusted EBITDA even though they reduced margin by 44 basis points in the quarter. He also noted that share-based compensation was close to $2.8 million and that the company raised full-year guidance based on stronger-than-expected third-quarter performance and continued operating trends.
Analysts focused on three themes: the durability of growth as assisted living occupancy matures, the pipeline for M&A versus greenfield expansion, and whether improved margins are sustainable. Management said organic growth comes from winning facilities as preferred pharmacy and then expanding adoption over time, and said the acquisition opportunity remains broad, with hundreds of independents and about 100 fitting their target profile. They also said there is no bias between organic and M&A in markets like Texas and Alabama, and that the recent margin lift came from a mix of longer-running reimbursement, purchasing, and plan-optimization initiatives rather than a one-time effect.
The bull case is that Guardian is still growing residents and prescriptions at a healthy clip while expanding into new markets and completing accretive acquisitions. Management sees a large fragmented market ahead, says its debt-free balance sheet supports self-funded growth, and believes better reimbursement economics can improve long-term stability. The company also raised full-year guidance and said its recent margin improvement reflects multiple operating levers working together.
The main risks discussed were continued IRA-related revenue pressure, elevated fuel and operating costs, and the possibility that recent margin gains may not repeat at the same magnitude. Management also said some of the recent EBITDA margin benefit came from longer-term initiatives that are unlikely to recur to the same degree in future quarters. Growth is still dependent on winning and expanding facility relationships, and management acknowledged that margin performance will ebb and flow as it continues to invest in new geography.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.7%
- Shares Outstanding
- 63.32M
- Float Shares
- 51.12M
of shares held by institutions
195 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 3.30M | ▲ 62.23K |
| Blackrock, Inc. | 2.42M | ▲ 842.80K |
| Wellington Management Group Llp | 2.22M | ▲ 492.46K |
| Vanguard Capital Management LLC | 1.45M | ▲ 66.96K |
| Vanguard Group Inc | 1.35M | ▲ 298.36K |
| Woodline Partners LP | 1.31M | 0 |
| T. Rowe Price Investment Management, Inc. | 1.17M | ▲ 51.02K |
| Loomis Sayles & Co L P | 1.07M | ▲ 201.05K |
| Geode Capital Management, LLC | 950.03K | ▲ 303.34K |
| Franklin Templeton Inc | 861.75K | ▼ 104.45K |
| Valiant Capital Management, L.P. | 803.40K | ▼ 383.26K |
| Timessquare Capital Management, LLC | 777.44K | ▼ 174.20K |
Held by 223 ETFs
Biggest fund positions in GRDN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Martin David Norman | sell | 4,800 |
| Nov 17, 26 | Martin David Norman | sell | 200 |
| Nov 17, 26 | Martin David Norman | sell | 4,800 |
| Nov 17, 26 | Martin David Norman | sell | 200 |
| Sep 27, 26 | Mudd William Franklin | other | 38,282 |
| Sep 27, 26 | Mudd William Franklin | other | 38,282 |
| Sep 27, 26 | Weir Robert | other | 23,450 |
| Sep 27, 26 | Weir Robert | other | 23,450 |
| Sep 27, 26 | Ackerman John | other | 1,413,939 |
| Sep 27, 26 | Ackerman John | other | 471,057 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GRDN coverage
Recent articles, reports, and earnings notes.
No research on GRDN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRDN report →Guardian Pharmacy Services, Inc. (GRDN) Hits Fresh High: Is There Still Room to Run?
zacks.com · Nov 18
Guardian Pharmacy Services, Inc. to Participate in Upcoming Citi Annual Global Healthcare Conference
businesswire.com · Nov 16
NBIX or GRDN: Which Is the Better Value Stock Right Now?
zacks.com · Nov 10
NBIX vs. GRDN: Which Stock Is the Better Value Option?
zacks.com · Nov 9
What Guardian Pharmacy Services (GRDN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 7
Guardian Pharmacy Services, Inc. (GRDN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 5
Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance
businesswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.